We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

GAIN: EnGAging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment

Miss a Webinar? Download the one you missed and watch it anytime.

Don't let your benefits expire!

Renew by March 31st.

 

Abstract Submission and Registration Open for WCLC 2015 on January 16

Featured Science and Communiqués

Early stage NSCLC patients with low tumor metabolic activity have longer survival.

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC) is associated with increased overall survival and a longer time before tumor recurrence. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

Early recall rates decline after second round of lung cancer screening.

The German Lung Cancer Screening Intervention Trial (LUSI) shows that the early repeat scan rate for suspicious findings decreased by more than 80% with the second and subsequent low-dose computed tomography (LDCT) screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison.

Concurrent chemoradiation treatment at high-volume facilities improves survival for non-small cell lung cancer patients.

Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.

Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC.

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient’s molecular and clinical characteristics by providing feedback from an expert panel.